| Pembrolizumab studied in …STUDIED_INderived200 of 2,183show all (up to 200) |
|---|
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · 2,183 trials list this drug (975 active) | — | — | Endocrine Neoplasm,Malignant Breast Neoplasm,Multiple Myeloma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833167Phase 3 · terminated Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) · 2,183 trials list this drug (975 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03834493Phase 3 · terminated Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) · 2,183 trials list this drug (975 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976323Phase 3 · completed Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) · 2,183 trials list this drug (975 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191096Phase 3 · terminated Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,183 trials list this drug (975 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,183 trials list this drug (975 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05562830Phase 1/Phase 2 · recruiting A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05753722Phase 1 · completed A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · 2,183 trials list this drug (975 active) | — | — | Malignant Bladder Neoplasm,Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961006Phase 2 · recruiting A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · 2,183 trials list this drug (975 active) | — | — | Cervical Adenocarcinoma,Cervical Squamous Cell Carcinoma,Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578649Phase 3 · not yet recruiting Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer · 2,183 trials list this drug (975 active) | — | — | Endometrial Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843550Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03349450Phase 2 · completed DPX-Survivac and Checkpoint Inhibitor in DLBCL · 2,183 trials list this drug (975 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03390504Phase 3 · active not recruiting A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253964Phase 2 · recruiting Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Non-Small Cell Squamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626479Phase 1/Phase 2 · completed Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) · 2,183 trials list this drug (975 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626518Phase 1/Phase 2 · completed Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) · 2,183 trials list this drug (975 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389514no longer available Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583708Phase 2 · recruiting Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer · 2,183 trials list this drug (975 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920356Phase 3 · recruiting A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06004245Phase 1 · recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 2,183 trials list this drug (975 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170788Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06234397Phase 1 · recruiting Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312137Phase 3 · recruiting A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312176Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) · 2,183 trials list this drug (975 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385080Phase 1/Phase 2 · recruiting A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06428409Phase 1/Phase 2 · recruiting A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) · 2,183 trials list this drug (975 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06525220Phase 3 · active not recruiting A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06545955Phase 3 · recruiting A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06579196Phase 1/Phase 2 · active not recruiting Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06758401Phase 3 · recruiting This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. · 2,183 trials list this drug (975 active) | — | — | Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868277Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · 2,183 trials list this drug (975 active) | — | — | Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198074Phase 3 · recruiting Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · 2,183 trials list this drug (975 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07216703Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) · 2,183 trials list this drug (975 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222566Phase 3 · recruiting Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Carcinoma,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276399Phase 3 · recruiting A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07360743Phase 2 · recruiting Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840456Phase 2 · not yet recruiting Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial · 2,183 trials list this drug (975 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03618550Phase 2 · recruiting Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma · 2,183 trials list this drug (975 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251117Phase 1/Phase 2 · active not recruiting GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04340882Phase 2 · active not recruiting Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624204Phase 3 · active not recruiting Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) · 2,183 trials list this drug (975 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05215340Phase 3 · active not recruiting Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · 2,183 trials list this drug (975 active) | — | — | Melanoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06096844Phase 3 · recruiting Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06123338Phase 2 · recruiting A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Esophageal Neoplasm,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890598Phase 3 · recruiting Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06901531Phase 3 · recruiting A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · 2,183 trials list this drug (975 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217496Phase 1 · not yet recruiting N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · 2,183 trials list this drug (975 active) | — | — | Early Stage HER2-Positive Breast Carcinoma,Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07475806Phase 2 · recruiting A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594015Phase 2 · recruiting Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance · 2,183 trials list this drug (975 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07840001Phase 2 · not yet recruiting Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma · 2,183 trials list this drug (975 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 2,183 trials list this drug (975 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04225117Phase 2 · active not recruiting A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357533Phase 3 · recruiting Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06452277Phase 3 · recruiting A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558214Phase 2 · recruiting OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial · 2,183 trials list this drug (975 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561386Phase 3 · recruiting A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618287Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Malignant Breast Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627647Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC · 2,183 trials list this drug (975 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07063745Phase 2/Phase 3 · recruiting A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion · 2,183 trials list this drug (975 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01174121Phase 2 · recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer · 2,183 trials list this drug (975 active) | — | — | Breast Carcinoma,Malignant Pancreatic Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03197506Phase 2 · active not recruiting Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma · 2,183 trials list this drug (975 active) | — | — | Glioblastoma,Gliosarcoma,Supratentorial Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03425565Phase 2 · completed A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Neoplasm,Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04671667Phase 2 · recruiting Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma,Laryngeal Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422794Phase 1 · recruiting Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05446298Phase 2 · active not recruiting ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer · 2,183 trials list this drug (975 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05913388Phase 2 · active not recruiting GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma · 2,183 trials list this drug (975 active) | — | — | Melanoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05977907Phase 2 · active not recruiting Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06151574Phase 3 · active not recruiting Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment · 2,183 trials list this drug (975 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06422806Phase 3 · recruiting Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas · 2,183 trials list this drug (975 active) | — | — | Dedifferentiated Liposarcoma,Soft Tissue Sarcoma of the Trunk and Extremities,Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06524544Phase 3 · recruiting A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · 2,183 trials list this drug (975 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06712316Phase 2/Phase 3 · recruiting Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06772623Phase 1/Phase 2 · recruiting Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06875310Phase 3 · recruiting A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218380Phase 3 · recruiting A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract · 2,183 trials list this drug (975 active) | — | — | Transitional Cell Carcinoma,Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07262619Phase 1/Phase 2 · recruiting EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 2,183 trials list this drug (975 active) | — | — | Gastric Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07415031Phase 2 · recruiting A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793179Phase 3 · active not recruiting Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04032418Phase 2 · active not recruiting Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04104893Phase 2 · active not recruiting A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation · 2,183 trials list this drug (975 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 2,183 trials list this drug (975 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04534205Phase 2/Phase 3 · active not recruiting A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 · 2,183 trials list this drug (975 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · 2,183 trials list this drug (975 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04708418Phase 2 · active not recruiting A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma · 2,183 trials list this drug (975 active) | — | — | Melanoma,Cutaneous Melanoma,Melanoma of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04977375Phase 1/Phase 2 · recruiting Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma · 2,183 trials list this drug (975 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05117242Phase 2 · terminated Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172258Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · 2,183 trials list this drug (975 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · 2,183 trials list this drug (975 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439836Phase 1 · recruiting Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736379Phase 1 · recruiting Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745882Phase 2 · recruiting Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04291755enrolling by invitation Development and Analysis of a Stool Bank for Cancer Patients · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04634877Phase 3 · active not recruiting Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) · 2,183 trials list this drug (975 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04752826Phase 1/Phase 2 · recruiting BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) · 2,183 trials list this drug (975 active) | — | — | Melanoma,Ovarian Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05027633Phase 2 · recruiting Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) · 2,183 trials list this drug (975 active) | — | — | Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · 2,183 trials list this drug (975 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06077760Phase 3 · active not recruiting A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161545Phase 2 · recruiting Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692738Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06767514Phase 3 · recruiting Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06906822Phase 2 · active not recruiting PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07730021Phase 1/Phase 2 · recruiting A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03486873Phase 3 · recruiting Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) · 2,183 trials list this drug (975 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04738487Phase 3 · terminated Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) · 2,183 trials list this drug (975 active) | — | — | Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239624Phase 2 · recruiting Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06780111Phase 1/Phase 2 · recruiting Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) · 2,183 trials list this drug (975 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06952504Phase 3 · recruiting A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) · 2,183 trials list this drug (975 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195695Phase 3 · recruiting Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365319Phase 2/Phase 3 · recruiting A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07639450Phase 1/Phase 2 · recruiting N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · 2,183 trials list this drug (975 active) | — | — | Bladder Urothelial Carcinoma,Invasive Bladder Giant Cell Urothelial Carcinoma,Malignant Bladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07695311Phase 1 · not yet recruiting EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT · 2,183 trials list this drug (975 active) | — | — | Ewing Sarcoma,Desmoplastic Small Round Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04613596Phase 2/Phase 3 · recruiting Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04670679Phase 1 · completed A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05155033Phase 2 · recruiting Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma · 2,183 trials list this drug (975 active) | — | — | Melanoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05764395Phase 2 · terminated Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06318286Phase 2 · active not recruiting Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma · 2,183 trials list this drug (975 active) | — | — | Pleural Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353997Phase 2 · recruiting Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06366347Phase 2 · recruiting ALPINE: Maintenance Letrozole/Abemaciclib · 2,183 trials list this drug (975 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07343596NA · recruiting Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery · 2,183 trials list this drug (975 active) | — | — | Malignant Oral Cavity Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07718854Phase 2 · recruiting Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Ovarian Neoplasm,Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811193Phase 2 · recruiting A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum · 2,183 trials list this drug (975 active) | — | — | Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07822373Phase 2 · not yet recruiting A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer · 2,183 trials list this drug (975 active) | — | — | Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07823491Phase 3 · not yet recruiting Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall · 2,183 trials list this drug (975 active) | — | — | Liposarcoma,Soft Tissue Sarcoma,Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03407144Phase 2 · active not recruiting Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) · 2,183 trials list this drug (975 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516279Phase 2 · active not recruiting Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 2,183 trials list this drug (975 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04462406Phase 2 · active not recruiting Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial · 2,183 trials list this drug (975 active) | — | — | Melanoma,Melanoma of Unknown Primary,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · 2,183 trials list this drug (975 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05410145Phase 1/Phase 2 · recruiting A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438459Phase 1/Phase 2 · recruiting GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites · 2,183 trials list this drug (975 active) | — | — | Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524935Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · 2,183 trials list this drug (975 active) | — | — | Ocular Melanoma,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06236425Phase 1 · completed TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC · 2,183 trials list this drug (975 active) | — | — | Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06806852Phase 1 · active not recruiting A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06899126Phase 3 · recruiting Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03149029Phase 2 · active not recruiting Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140526Phase 1/Phase 2 · active not recruiting Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191135Phase 2 · terminated Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04977453Phase 1/Phase 2 · recruiting GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Urothelial Carcinoma,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05067283Phase 1 · recruiting A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05197322Phase 2 · active not recruiting NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer · 2,183 trials list this drug (975 active) | — | — | Colon Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721755Phase 3 · active not recruiting Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck · 2,183 trials list this drug (975 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06137144Phase 1/Phase 2 · recruiting AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. · 2,183 trials list this drug (975 active) | — | — | Lymphoma,Anaplastic Large Cell Lymphoma,Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06236438Phase 2/Phase 3 · recruiting Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06242834Phase 2 · active not recruiting Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · 2,183 trials list this drug (975 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06246968Phase 1 · recruiting A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282575Phase 3 · recruiting Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04485013Phase 1 · active not recruiting TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers · 2,183 trials list this drug (975 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081609Phase 1/Phase 2 · active not recruiting A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05186974Phase 2 · active not recruiting Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226598Phase 3 · terminated Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365581Phase 1 · recruiting A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer · 2,183 trials list this drug (975 active) | — | — | Gastric Adenocarcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06764875Phase 3 · recruiting A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer · 2,183 trials list this drug (975 active) | — | — | Gastroesophageal Junction Adenocarcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843447Phase 1/Phase 2 · recruiting A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · 2,183 trials list this drug (975 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07247110Phase 1 · recruiting A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · 2,183 trials list this drug (975 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07566156Phase 3 · recruiting Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) · 2,183 trials list this drug (975 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07673887Phase 3 · recruiting A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer · 2,183 trials list this drug (975 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07815665Phase 2/Phase 3 · recruiting A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma · 2,183 trials list this drug (975 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04795661Phase 2 · active not recruiting Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. · 2,183 trials list this drug (975 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04865887Phase 2 · recruiting Pembrolizumab and Lenvatinib in Advanced Cervical Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665595Phase 3 · terminated A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05766371Phase 2 · recruiting Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer · 2,183 trials list this drug (975 active) | — | — | Prostate Neoplasm,Malignant Prostate Neoplasm,Prostate Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05852691Phase 2 · active not recruiting A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06057038Phase 1 · active not recruiting A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06797635Phase 2 · recruiting Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) · 2,183 trials list this drug (975 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07026474Phase 3 · recruiting Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652242Phase 1 · recruiting Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05119296Phase 2 · active not recruiting Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer · 2,183 trials list this drug (975 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633654Phase 3 · recruiting Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635824Phase 3 · active not recruiting Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) · 2,183 trials list this drug (975 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06699836Phase 2 · active not recruiting CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen · 2,183 trials list this drug (975 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166601Phase 1 · recruiting M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07541170Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07668154Phase 2 · recruiting A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679360Phase 3 · recruiting A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer · 2,183 trials list this drug (975 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03897881Phase 2 · active not recruiting An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) · 2,183 trials list this drug (975 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05732831Phase 1/Phase 2 · recruiting Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789082Phase 1/Phase 2 · recruiting A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119581Phase 3 · recruiting A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06345729Phase 3 · recruiting A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561685Phase 1 · recruiting A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors · 2,183 trials list this drug (975 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06793215Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer · 2,183 trials list this drug (975 active) | — | — | Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07361510Phase 3 · recruiting A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) · 2,183 trials list this drug (975 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07807163Phase 2 · recruiting A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC · 2,183 trials list this drug (975 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07807345Phase 1 · not yet recruiting Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic · 2,183 trials list this drug (975 active) | — | — | Malignant Breast Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |